# US 2026/0061023 A1 · Methods and compositions for the prevention or treatment of barth syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061023 A1
- Document ID: US20260061023A1
- Status: Published application
- Kind: A1
- Application number: 19/074,720
- Filed: 2025-03-10
- Published: 2026-03-05
- Earliest claimed: 2013-03-01
- Assignees: Stealth BioTherapeutics Inc.
- Applicants: Stealth BioTherapeutics Inc.
- Inventors: D. Travis Wilson; Mark Bamberger
- Web page: https://patentgrep.com/patent/US20260061023A1

## CPC

- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.

## Claims

### Claim at position 1

-26. (canceled)

### Claim 27

A method for improving LV function in a subject having Barth Syndrome, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the peptide is administered daily for 6 weeks or more.

### Claim 29 (depends on 27)

The method of claim 27, wherein the peptide is administered daily for 12 weeks or more.

### Claim 30 (depends on 27)

The method of claim 27, wherein the subject is human.

### Claim 31 (depends on 27)

The method of claim 27, wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly.

### Claim 32 (depends on 27)

The method of claim 27, wherein the pharmaceutically acceptable salt comprises acetate or trifluoroacetate salt.

### Claim 33

A method for improving the rate of mitochondrial ATP synthesis in a subject having Barth Syndrome, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the peptide is administered daily for 6 weeks or more.

### Claim 35 (depends on 33)

The method of claim 33, wherein the peptide is administered daily for 12 weeks or more.

### Claim 36 (depends on 33)

The method of claim 33, wherein the subject is human.

### Claim 37 (depends on 33)

The method of claim 33, wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraperitoneally, or intramuscularly.

### Claim 38 (depends on 33)

The method of claim 33, wherein the pharmaceutically acceptable salt comprises acetate or trifluoroacetate salt.
